Paramus-based Yamanouchi Pharma America received an approvable letter from the U.S. Food and Drug Administration for its conivaptan hydrochloride injection, an investigational treatment for ...

Although fluid restriction is standard first-line treatment, it is often ineffective in patients with hyponatremia and syndrome of inappropriate antidiuresis (SIAD).

The syndrome of inappropriate antidiuretic hormone (SIADH) in the setting of malignancy is a well-described paraneoplastic syndrome most commonly resulting from ectopic tumor production of ...

FDA Approves Astellas Pharma's Vaprisol for the Treatment of Hypervolemic Hyponatremia DEERFIELD, Ill., March 2 -- Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration ...

Data are based on the largest inpatient cohort with SIAD reported to date. Oral urea effectively treats hyponatremia in patients with the syndrome of inappropriate antidiuresis (SIAD) who fail to ...

Empagliflozin is a potential treatment for outpatients with chronic hyponatremia due to the syndrome of inappropriate antidiuresis (SIAD), new data suggest. The sodium-glucose cotransporter 2 (SGLT2) ...

Once the differential diagnosis is made, treatment can be initiated. While many may believe it is the sole responsibility of the physician or APN to diagnose the hyponatremic patient, it is important ...

DEAR DR. ROACH: My mother’s blood test has a sodium level of 130 mEq/L. She is not on diuretics, and she does not have heart or kidney problems. She is on thyroid medication and omeprazole. Do I need ...

In older adults, low sodium often results from certain medications, kidney issues, or infections. Because multiple factors may contribute, treatment depends on identifying the underlying cause. Sodium ...